Summary
Regeneron Pharmaceuticals, Inc. filed an 8-K on October 31, 2003, to report a financial results press release dated October 30, 2003. This filing primarily serves to correct a minor error present in a prior press release issued on September 29, 2003. Investors should note that this 8-K itself does not contain new financial data but rather an amendment/clarification to previously released information concerning the fiscal quarter ended September 30, 2003. While the specific details of the financial results and the nature of the error are not detailed within this 8-K document itself (as they are in the attached press release, Exhibit 99(a)), the filing signifies the company's commitment to accurate financial reporting and regulatory disclosure. Investors interested in the updated financial performance for the quarter ending September 30, 2003, should refer to the attached press release.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. filed an 8-K on October 31, 2003.
- 2The filing's primary purpose is to attach a press release dated October 30, 2003.
- 3This press release provides updated financial results for the fiscal quarter ended September 30, 2003.
- 4The October 30, 2003 press release corrects a minor error from a previous release on September 29, 2003.
- 5The 8-K itself serves as a disclosure mechanism for the corrected financial information.
- 6The filing is in accordance with Regulation FD and Disclosure of Operations and Financial Condition.
- 7Investors should consult the referenced press release (Exhibit 99(a)) for the specific financial details and the nature of the correction.